OBJECTIVE: To determine the complications and nonrecurrence rates following superficial lamellar keratectomy, bulbar conjunctivectomy, and adjunctive carbon dioxide (CO(2)) photoablation for corneolimbal squamous cell carcinoma (SCC) in the horse. STUDY DESIGN: Retrospective study. Sample population Twenty-four horses with corneolimbal SCC. PROCEDURE: Medical records of horses diagnosed with corneolimbal SCC that was surgically excised and where CO(2) photoablation was used as an adjunctive therapy from 2000 to 2007 were reviewed. Signalment, prior therapy, tumor location and size, complications, and recurrence of SCC were recorded. RESULTS: The Thoroughbred was the most commonly (25%) represented breed. Lesions were >10 mm in diameter in 70.8% of cases. Eight horses (33.3%) had neoplastic cells extending to the deep margin of the keratectomy. All horses were available for follow-up for an average ± standard deviation of 40.7 ± 25 months. Four horses (16.7%) developed a recurrence of SCC. Three of these four horses underwent repeat keratectomy and CO(2) photoablation, one each, at 4 months, 1, and 2 years following the initial procedure. One horse underwent enucleation 8 months following the initial procedure. CONCLUSIONS AND CLINICAL RELEVANCE: As an adjunctive therapy, CO(2) photoablation was successful in 87.5% of the horses following a single procedure and in a total of 91.7% following a second therapeutic application. CO(2) photoablation appears to be effective as an adjunctive therapy following removal of large corneolimbal SCC in the horse and in cases in which all tumor cells were not excised.
OBJECTIVE: To determine the complications and nonrecurrence rates following superficial lamellar keratectomy, bulbar conjunctivectomy, and adjunctive carbon dioxide (CO(2)) photoablation for corneolimbal squamous cell carcinoma (SCC) in the horse. STUDY DESIGN: Retrospective study. Sample population Twenty-four horses with corneolimbal SCC. PROCEDURE: Medical records of horses diagnosed with corneolimbal SCC that was surgically excised and where CO(2) photoablation was used as an adjunctive therapy from 2000 to 2007 were reviewed. Signalment, prior therapy, tumor location and size, complications, and recurrence of SCC were recorded. RESULTS: The Thoroughbred was the most commonly (25%) represented breed. Lesions were >10 mm in diameter in 70.8% of cases. Eight horses (33.3%) had neoplastic cells extending to the deep margin of the keratectomy. All horses were available for follow-up for an average ± standard deviation of 40.7 ± 25 months. Four horses (16.7%) developed a recurrence of SCC. Three of these four horses underwent repeat keratectomy and CO(2) photoablation, one each, at 4 months, 1, and 2 years following the initial procedure. One horse underwent enucleation 8 months following the initial procedure. CONCLUSIONS AND CLINICAL RELEVANCE: As an adjunctive therapy, CO(2) photoablation was successful in 87.5% of the horses following a single procedure and in a total of 91.7% following a second therapeutic application. CO(2) photoablation appears to be effective as an adjunctive therapy following removal of large corneolimbal SCC in the horse and in cases in which all tumor cells were not excised.
Authors: Moriel H Singer-Berk; Kelly E Knickelbein; Zachary T Lounsberry; Margo Crausaz; Savanna Vig; Nikhil Joshi; Monica Britton; Matthew L Settles; Christopher M Reilly; Ellison Bentley; Catherine Nunnery; Ann Dwyer; Mary E Lassaline; Rebecca R Bellone Journal: Int J Genomics Date: 2019-09-15 Impact factor: 2.326
Authors: Margo Crausaz; Thomas Launois; Kathryn Smith-Fleming; Annette M McCoy; Kelly E Knickelbein; Rebecca R Bellone Journal: Genes (Basel) Date: 2020-12-05 Impact factor: 4.096
Authors: Steve Horvath; Amin Haghani; Sichong Peng; Erin N Hales; Joseph A Zoller; Ken Raj; Brenda Larison; Todd R Robeck; Jessica L Petersen; Rebecca R Bellone; Carrie J Finno Journal: Nat Commun Date: 2022-01-10 Impact factor: 14.919